Organovo (ONVO) 8-K Regulation FD Disclosure

Changing the Shape of

Medical Research

and Practice

Keith Murphy

Chairman and Chief Executive Officer

0

©

Copyright 2012, Organovo Holdings, Inc.  This report is solely for the use of intended audience.  No part

of it may be circulated, quoted, or reproduced for distribution outside the organization without prior

written approval from Organovo Holdings, Inc.

Exhibit 99.1

November 23, 2012

SAFE HARBOR STATEMENT

1

©

Copyright 2012  Organovo Holdings, Inc.

OTC QX: ONVO

This

presentation

contains

“forward-looking

statements”

that

involve

significant

risks

and

uncertainties.

All

statements

other

than

statements

of

historical

fact

are

statements

that

could

be

deemed

forward-looking

statements,

including,

but

not

limited

to,

statements

regarding

the

results

and

benefits

of

the

Company’s

tender

offer

and

its

prospective

performance,

opportunities

and

business

outlook.

Any

forward-looking

statements

contained

herein

are

based

on

current

expectations,

but

are

subject

to

a

number

of

risks

and

uncertainties.

The

risks

and

uncertainties

that

could

cause

the

Company’s

actual

future

results

to

differ

materially

from

current

expectations

include,

but

are

not

limited

to,

risks

and

uncertainties

relating

to

the

Company's

ability

to

develop,

market

and

sell

products

based

on

its

technology;

the

expected

benefits

and

efficacy

of

the

Company’s

products

and

technology;

the

availability

of

substantial

additional

funding

for

the

Company

to

continue

its

operations

and

to

conduct

research

and

development,

clinical

studies

and

future

product

commercialization;

the

Company's

failure

to

achieve

its

business,

research,

product

development,

regulatory

approval,

marketing

and

distribution

plans

and

strategies;

and

the

successful

completion

of

the

tender

offer.

These

and

other

factors

are

identified

and

described

in

more

detail

in

the

Company’s

filings

with

the

SEC,

including

its

current

report

on

Form

8-K/A

filed

with

the

SEC

on

May

11,

2012.

These

forward-looking

statements

are

made

as

of

the

date

of

this

presentation,

and

the

Company

does

not

undertake an obligation to update these forward-looking statements after such date.

2

©

Copyright 2012  Organovo Holdings, Inc.

3

Organovo has made tremendous progress

In past 12 months

Signed up United Therapeutics

Delivered tissue blocks to Pfizer under our collaboration

NIH Grant for 3D liver

Successful financing and reverse merger

Attracted top executives and doubled staff

Opened 15,000 sq ft new facility

Completed Phase 1 market research

OTC QX uplist

©

Copyright 2012  Organovo Holdings, Inc.

4

Market research reveals opportunity

Cell Assay Products

Identified specific market opportunity >$500M by 2018

†

High unmet customer need and market opportunity

identified that can be met with 3D cell assay products

†

Overall cell biology market growing to $17B by 2016,

12% CAGR

†

Disease models

Qualitative market research conducted to target initial

opportunities –

including Oncology

Focus on Pharma co. “lead optimization”

as entry point

©

Copyright 2012  Organovo Holdings, Inc.

†

Source: 2012 Scientia Advisors market research, sponsored by Organovo

5

Organovo milestones in 2013

Organovo will keep delivering

Major new data on 3D liver by Q2 2013

Expanding the set of current partners

Reaching upstream in drug discovery to partner with

academics –

now pursuing partnerships

Technology partnerships to develop bioprinting

Collaborate with 3D peers in non-bio spaces

Company pursuing uplisting to NASDAQ or NYSE

©

Copyright 2012  Organovo Holdings, Inc.

6

Goals of tender offer

Clean up derivative liability

Outstanding warrants from Q1 offering create derivative

liability for company

Company currently is below shareholder equity

requirements for listing on NASDAQ or NYSE MKT

as a result

Raise funds

End Q3 Cash on hand $7.7M

Tender offer can raise up to $11.5M gross

Company net burn of ~$7-8M/year expected in 2013

†

Source: Scientia Advisors study, commissioned by company

©

Copyright 2012  Organovo Holdings, Inc.

Seeking uplisting to major exchange

7

Seeking uplisting to major exchange

8

NYSE MKT Initial Listing Standards

Organovo Contacts:

Keith Murphy, CEO

(858) 550-9993

kmurphy@organovo.com

Barry Michaels, CFO

(858) 224-1003

bmichaels@organovo.com

Website: 

http://www.organovo.com

9

Enabling tissue on demand

OTC QX: ONVO

©

Copyright 2012  Organovo Holdings, Inc.